Market Overview
MRFR/Market Research Future expects the Autism Disorder and Treatment Market to achieve a growth rate of 4.37% between 2017 and 2023 (review period).
Growth Boosters and Deterrents
Studies have revealed that close to 3.5 million adults and children are suffering from autism in North America. The global market for autism disorder and treatment is anticipated to expand considerably in the coming five years, on account of increased efforts given by the authoritative as well as advocacy groups and the soaring number of Applied Behaviour Analysis (ABA) treatment programs along with associated centers. Surge in the number of insurance coverages, and the frequent introduction of more effective and advanced drugs for treating patients also benefit the global industry.
Mounting awareness about autism disorder has prompted people to go for early detection, leading to faster diagnosis. This is partly due to the soaring number of awareness programs and campaigns backed by the government worldwide. These initiatives by the government also ensure that ASD affected children obtain early access to effective therapies. Surge in healthcare events related to autism, paired by the continuous focus on product innovation and the rise in research & development/R&D activities also act in favor of the global market.
There has been a significant escalation in researches and clinical trials with respect to autism in recent years, with the primary focus on finding more cost-effective and coordinated approaches that facilitate early identification, screening, as well as intervention. Most of the studies focus on identifying any relation or pattern between the patients and their families. Apart from these studies, players also indulge in a few competitive measures that include mergers, partnerships and acquisitions as well as new launches of products, drugs and services, with the aim to capture a bigger share in the global market. For reference, in February 2021, Ontario is set to introduce its latest autism services program by March 2021, which will start with 600 children. This program will be offering the patients with need-based services such as speech language pathology, occupational therapy and applied behaviour analysis.
Free Sample Copy: https://www.marketresearchfuture.com/sample_request/1605
Market Segmentation
The autism disorder and treatment industry can be considered for type, treatment type, and drugs.
The primary types of autism disorder are Pervasive Developmental Disorder, Asperger Syndrome, and more. The lead has been secured by the pervasive developmental disorder segment, which can expect to procure a CAGR of 4.73% from 2017 to 2023.
In terms of treatment type, the market can be distributed into hyperbaric oxygen therapy, ABA (applied behavioral analysis), oxytocin therapy, chelation therapy, and others. ABA (Applied Behavior Analysis) programs are currently the most widespread treatment type and have exhibited successful outcomes. Revenues generated by ABA (applied behavioral analysis) programs have managed to outpace the sales of other treatment options as well as prescription drugs generally used for autism symptoms. As a result, the ABA segment can take the lead in the global market and grow at a rate of 4.82% in the coming years.
Main drugs taken for the treatment of autism disorder are anti-convulsant, SSRIs, anti-psychotic and stimulants. Anti-psychotics drugs can be split into Risperidone and Abilify (aripiprazole). Increasing launch of new antipsychotic compounds coupled with the large-scale investments with respect to R&D have led to the strong demand for anti-psychotic drugs. As a result, the segment can thrive at a rate of 3.95% during the evaluation period.
Browse Complete Report:https://www.marketresearchfuture.com/reports/autism-disorder-and-treatment-market-1605
Regional Insight
The market for autism disorder and treatment has been regionally segmented into Asia Pacific/APAC, Americas, MEA or Middle East & Africa and Europe.
Americas is the most lucrative market for autism disorder and treatment, followed by Europe. In the American market, North America has emerged on the top with the highest revenue generation owing to the high number of screening procedures conducted for autism. Also, the surge in FDA approvals promoting a rise in launches of new atypical anti-psychotic drugs like Namenda and Latuda could also bolster the market size in the region over the next several years.
Asia Pacific can gain the fastest growth rate, as the non-pharmacological treatment segment has been gaining traction, backed by several government policies along with rising per capita income. In view of the accelerated demand for effective treatment options and the increasing burden of the condition, players are coming up with innovative products to cater to the unmet needs of the patients in the region.
Top Firms
Some of the leading firms in the global industry are Pfizer inc. (U.S.), Eli Lilly and Company (U.S.). Allergan (Ireland), Consern Pharma Private Limited (India), GlaxoSmithKline plc (U.K), Teva Pharmaceutical Industries Ltd. (Israel), Merck & CO Inc. (U.S.), to name a few.
No comments:
Post a Comment